How many drugs treat Pneumonia due to Pseudomonas?

Drug Landscape tracks 10 marketed treatments for Pneumonia due to Pseudomonas (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pneumonia-due-to-pseudomonas.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pneumonia due to Pseudomonas — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pneumonia due to Pseudomonas (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumonia due to Pseudomonas, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
AZLOCILLIN	AZLOCILLIN	Bayer Pharmaceuticals Corp	azlocillin		1982-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Pneumonia due to Pseudomonas
Pfizer · 2 drugs in Pneumonia due to Pseudomonas
Bristol-Myers Squibb · 2 drugs in Pneumonia due to Pseudomonas
Merck & Co. · 2 drugs in Pneumonia due to Pseudomonas
Baxter · 2 drugs in Pneumonia due to Pseudomonas
Pai Holdings Pharm · 2 drugs in Pneumonia due to Pseudomonas
Sterimax · 1 drug in Pneumonia due to Pseudomonas
Tel-Aviv Sourasky Medical Center · 1 drug in Pneumonia due to Pseudomonas
University Hospital Tuebingen · 1 drug in Pneumonia due to Pseudomonas
University Hospital, Lille · 1 drug in Pneumonia due to Pseudomonas
Assistance Publique - Hôpitaux de Paris · 1 drug in Pneumonia due to Pseudomonas
Bayer AG · 1 drug in Pneumonia due to Pseudomonas

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumonia due to Pseudomonas:

Cite this brief

Drug Landscape (2026). Pneumonia due to Pseudomonas — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia-due-to-pseudomonas. Accessed 2026-06-10.

Pneumonia due to Pseudomonas full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing